Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.

Abstract

BACKGROUND\nMeningococcal serogroup B (MenB) has emerged as the leading cause of invasive meningococcal disease (IMD) in several countries following the release of effective vaccines against serogroups A, C, W, and Y. In 2013, however, the first multicomponent MenB vaccine (Bexsero®) was licensed in Europe.\n\n\nAIM\nTo review the evidence on the cost-effectiveness of vaccination against MenB.\n\n\nMETHODS\nSearches were performed in MEDLINE, EMBASE, Web of Science, NHS EED, Econlit, Tufts CEA registry, and HTA. Three reviewers independently screened and selected studies. Using a narrative synthesis, studies were categorized by vaccination strategies. The quality of included studies was assessed using the Comparative Health Economics Evaluation Reporting Standards (CHEERS) checklist.\n\n\nRESULTS\n13 studies were included. Ten studies were conducted in the European region and three in the Americas. None of the vaccination strategies were considered cost-effective. Including herd effects improved value for money for MenB vaccines. Routine infant vaccination was the most effective short-term strategy, however, adolescent strategies offered the best value for money. Without herd immunity, routine infant vaccination had the lowest incremental cost-effectiveness ratio estimates.\n\n\nCONCLUSION\nRoutine MenB vaccination does not offer substantial value for money, mainly due to high vaccine costs and low disease incidence.